お知らせ • Jun 29
Tango Therapeutics, Inc. Announces First Patient Dosed in Phase 1/2 Trial of Tng462 Plus Revolution Medicines'daraxonrasib or Zoldonrasib in Patients with Ras-Mutant Mtap-Deleted Pancreatic or Lung Cancer
Tango Therapeutics, Inc. announced that the first patient has been dosed in the Phase 1/2 trial of TNG462 and Revolution Medicines' daxonrasib (RAS(ON) multi-selective inhibitor) or zoldonrasib (RAS (ON) G12D-selective inhibitor) in patients with MTAP-deleted and RAS mutant metastatic pancreatic or lung cancer. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: the benefits of product candidates (including TNG462 as a monotherapy and in combination with other therapies) seen in preclinical tests and analyses may not be evident when tested in later preclinical studies or in clinical trials or when used in broader patient populations (if approved for commercial sale); Tango has limited experience conducting clinical trials (and does and will continue to rely on a third party to operate its clinical trials) and may not be able to commence its clinical trials (including opening clinical trial sites, dosing the first patient, and continued enrollment and dosing of an adequate number of clinical trial participants) when expected, may not be able to continue dosing, initiate dose escalation and/or dose expansion on anticipated timelines, and may not generate or report clinical trial results (including final, initial, interim, updated clinical trial results or additional safety and efficacy data and the establishment of proof-of-mechanism and proof-of-concept) in the anticipated timeframe (or at all); future clinical trial data releases may differ materially from initial or interim data from current and future clinical trials; Tango has a limited operating history and has not generated any revenue to date from product sales, and may never become profitable; other companies may be able to identify and develop product candidates more quickly than the Company and commercially introduce the product prior to the Company; the Company may not be able to identify development candidates on the schedule it anticipates due to technical, financial or other reasons; the Company may not beable to file INDs for development candidates on time, or at all, due to technical or financial reasons or otherwise; the Company may utilize cash resources more quickly than anticipated; Tango will need to raise capital in the future and if are unable to raise capital when needed or on attractive terms, would be forced to delay, scale back or discontinue some of development programs or future commercialization efforts (which may delay filing of INDs, dosing patients, initiation of dose expansion, reporting clinical trial results and filing new drug applications); the Company may be unable to advance preclinical development programs into and through the clinic for safety or efficacy reasons or commercialize product candidates or may experience significant delays in doing so as a result of factors beyond Tango's control; the Company may not be capable to realize the benefits of orphan drug or Fast Track designation (and such designations may not advance any anticipated approval timelines); the expected benefits of product candidates in patients as single agents and/or in combination may not be realized; the Company may experience delays or difficulties in the initiation, enrollment, or dosing of patients in clinical trials or the announcement of clinical trial results, Tango may not identify or discover additional product candidates or may expend limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success; the Company's product candidates may cause adverse or other undesirable side effects (or may not show requisite efficacy) that could, among other things, delay or prevent regulatory approval; dependence on one or a limited number third parties for conducting clinical trials and producing drug substance and drug product (including drug substance and drug product (including drug substance, which is currently sole sourced) increases the risk that will not have sufficient quantities of product candidates or products or at an acceptable cost; government regulation may negatively impact the Company's business, including the potential approval of the BIOSECURE Act; business, financial condition and results of operations may be negatively impacted by global economic conditions, including global economic conditions, including trade restrictions and inflation rates, including trade restrictions and economic conditions, including trade restrictions, including trade restrictions and inflation rate, including trade restrictions and inflation and inflation rates, and inflation rates; government regulation may be negatively impact the potential approval; government regulation may negatively impact.